使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Ladies and gentlemen, thank you for standing by. My name is Abby. I'll be your conference operator today.
各位女士、先生,感謝您稍候等候。我叫 Abby。今天將由我擔任本次電話會議的接線員。
At this time, I would like to welcome everyone to the Doximity fourth-quarter 2026 earnings call.
此刻,我謹代表公司歡迎各位參加 Doximity 2026 年第四季財報電話會議。
(Operator Instructions)
(接線員指示)
Thank you. I would now like to turn the conference over to Perry Gold, Vice President of Investor Relations. You may begin.
謝謝。接下來我想把電話會議交給投資人關係副總裁 Perry Gold。您可以開始了。
Perry Gold - Vice President - Investor Relations
Perry Gold - Vice President - Investor Relations
Thank you, operator. Hello and welcome to Doximity's fiscal 2026 fourth-quarter earnings call.
謝謝,接線員。各位好,歡迎參加 Doximity 2026 會計年度第四季財報電話會議。
With me on the call today are Jeff Tangney, Co-Founder and CEO of Doximity; and Matt Sonefeldt, our new CFO.
今天與我一同出席電話會議的有 Doximity 共同創辦人兼執行長 Jeff Tangney,以及我們新任財務長 Matt Sonefeldt。
A complete disclosure of our results can be found in our press release issued earlier today, as well as in our related Form 8-K, along with a copy of our prepared remarks, all available on our website at investors.doximity.com.
我們的完整業績揭露可見於今日稍早發布的新聞稿,以及相關的 Form 8-K(並附上我們事先準備的講稿),皆已公布於我們的網站 investors.doximity.com。
As a reminder, today's call is being recorded. A replay will be available on our website.
提醒各位,今天的電話會議將被錄音。重播將於我們的網站提供。
As part of our comments today, we will be making forward-looking statements. These statements are based on management's current views, expectations, and assumptions; and are subject to various risks and uncertainties.
在今天的發言中,我們將提出前瞻性陳述。這些陳述係基於管理團隊目前的觀點、預期與假設,並可能受到各種風險與不確定性影響。
Actual results may differ materially. We disclaim any obligation to update any forward-looking statements or outlook.
實際結果可能出現重大差異。我們不承擔更新任何前瞻性陳述或展望的義務。
Please refer to the risk factors in our annual report on Form 10-K; any subsequent Form 10-Qs; and our other reports and filings with the SEC that may be filed from time to time, including our upcoming filing on Form 10-K.
請參閱我們 Form 10-K 年報中的風險因素、其後提交的任何 Form 10-Q,以及我們不時向美國證券交易委員會(SEC)提交的其他報告與文件(包括我們即將提交的 Form 10-K)。
Our forward-looking statements are based on assumptions that we believe to be reasonable as of today's date, May 13, 2026.
我們的前瞻性陳述係基於我們截至今日(2026 年 5 月 13 日)認為合理的假設。
Of note, it is Doximity's policy to neither reiterate nor adjust the financial guidance provided on today's call, unless it is also done through a public disclosure, such as a press release or through the filing of a Form 8-K.
特別說明,Doximity 的政策是:除非同時透過公開揭露(例如新聞稿或提交 Form 8-K)進行,否則不會在今日電話會議中重申或調整所提供的財務指引。
Today, we will discuss certain non-GAAP metrics that we believe aid in the understanding of our financial results. A historical reconciliation to comparable GAAP metrics can be found in today's earnings release.
今天我們將討論若干非 GAAP 指標,我們相信這些指標有助於理解我們的財務結果。與可比 GAAP 指標的歷史調節表可見於今日的財報新聞稿。
Finally, during the call, we may offer incremental metrics to provide greater insights into the dynamics of our business. These details may be one-time in nature. We may or may not provide updates on those metrics in the future.
最後,在電話會議期間,我們可能會提供額外指標,以便更深入說明我們業務的動態。這些細節可能屬一次性資訊。未來我們可能會、也可能不會更新這些指標。
I would now like to turn the call over to our CEO and Co-Founder, Jeff Tangney. Jeff?
接下來我想把電話會議交給我們的執行長兼共同創辦人 Jeff Tangney。Jeff?
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Thanks, Perry. Thanks, everyone, for joining our fourth-quarter earnings call.
謝謝,Perry。也謝謝各位參加我們的第四季財報電話會議。
Today, I'll cover our financials, our AI investment year, and a couple of key hires.
今天我將涵蓋我們的財務表現、我們的 AI 投資年度,以及幾項關鍵人事任命。
First, our financials: Q4 ended above the high end of our guidance, with a record $107 million in free cash flow, our first ever nine-digit free cash flow quarter.
首先是財務表現:第四季表現高於我們指引區間的上緣,自由現金流創下 1.07 億美元新高,這也是我們史上首次單季自由現金流達到九位數。
Revenue was $145 million in Q4, up 5%, year on year. For the full fiscal year ended March 31, revenue was $645 million, up 13%, year on year.
第四季營收為 1.45 億美元,年增 5%。截至 3 月 31 日的整個會計年度,營收為 6.45 億美元,年增 13%。
On the bottom line, our adjusted EBITDA margin was 45% in Q4 and 55% for the full year. Our full year free cash flow was $317 million, up 19%, year on year.
在獲利方面,第四季調整後 EBITDA 利潤率為 45%,全年為 55%。全年自由現金流為 3.17 億美元,年增 19%。
Okay. Now, to our AI strategy -- what we're calling our AI investment year -- let me start with the headline: Nearly half of all US doctors now work at hospitals that buy our workflow or scheduling tools.
好的。接下來談我們的 AI 策略——我們稱之為「AI 投資年度」。先講重點:目前美國近一半的醫師,任職於採購我們工作流程或排班工具的醫院。
As we've become more integrated into their EHRs, we're increasingly a daily use for them. Our benchmark workflow engagement reached over 800,000 unique quarterly active prescribers in Q4, up roughly 30% year on year, a significant acceleration from the high-single-digit growth we saw a year ago.
隨著我們與他們的 EHR(電子病歷系統)整合程度加深,我們愈來愈成為他們每日使用的工具。我們的基準工作流程互動指標在第四季達到超過 80 萬名不重複的季度活躍開立處方者,年增約 30%,相較於一年前的高個位數成長,增速明顯加快。
Nearly half of all these active prescribers used our AI tools in Q4.
這些活躍開立處方者中,近一半在第四季使用了我們的 AI 工具。
We saw record-high engagement across our entire platform last quarter, as doctors increasingly turned to us to be their AI assistant. In the nine months since we acquired Pathway, our [AI Search and Scribe] active users have tripled. Last month, these users averaged 31 queries each, nearly double January's usage.
上季我們整個平台的互動程度創下新高,因為醫師愈來愈多地把我們當作他們的 AI 助理。自從我們收購 Pathway 以來的九個月內,我們的 [AI Search and Scribe] 活躍使用者已成長至三倍。上個月,這些使用者平均每人進行 31 次查詢,幾乎是 1 月使用量的兩倍。
In a side-by-side clinical search evaluation completed by 4,700 physician residents last quarter, respondents chose our AI answers over our nearest competitor by [2:1]. They prefer our built-in drug reference and peer review.
在上一季由 4,700 名住院醫師完成的臨床搜尋並列評估中,受訪者選擇我們的 AI 答案勝過最接近的競爭對手,比例為[2:1]。他們偏好我們內建的藥物參考資料與同儕審查。
Hospitals are choosing us, too. As of today, 140 health systems have purchased our [Clinical AI Suite], including seven of the top 20 hospitals. Over 250,000 prescribers now have access to our Clinical AI Suite in a single, hospital-approved, HIPAA-compliant workflow.
醫院也在選擇我們。截至今日,已有 140 個醫療體系採購我們的 [Clinical AI Suite],其中包括前 20 大醫院中的 7 家。目前已有超過 25 萬名開立處方者可在單一、經醫院核准且符合 HIPAA 的工作流程中使用我們的 Clinical AI Suite。
The race is on to build the best Scribe and Search AI for doctors. Our 380-person R&D team is all in to win this. You'll see a slew of new physician-led features and agents from us in the coming months.
為醫師打造最佳的 Scribe 與 Search AI 的競賽已經開始。我們 380 人的研發團隊全力投入,目標就是勝出。未來幾個月,各位將看到我們推出一系列由醫師主導的新功能與代理(agents)。
I'm excited to share two of them today:
今天我很高興分享其中兩項:
First, we've partnered with Aledade to provide value-based care AI agents for their network of thousands of primary care organizations. They'll use our Scribe and Clinical AI Suite to save time and money. With them, we're bringing AI assistance not just to big hospitals but to small-town family physicians, too.
第一,我們與 Aledade 合作,為其由數千家基層醫療機構組成的網路提供價值導向照護(value-based care)AI 代理。他們將使用我們的 Scribe 與 Clinical AI Suite 來節省時間與成本。透過這項合作,我們把 AI 協助不僅帶到大型醫院,也帶到小鎮的家庭醫師。
Second, we've added e-prescribing to our platform so our doctors can write a prescription in a few taps after a telehealth call or while on the go. We save the doctor time and the patient money by letting the patient choose their preferred pharmacy from their phone.
第二,我們在平台上新增了電子處方(e-prescribing)功能,讓醫師在遠距醫療通話後或外出途中,只需幾次點擊就能開立處方。我們讓病患可用手機選擇偏好的藥局,藉此為醫師節省時間、也為病患節省費用。
Over 1,000 prescribers have participated in our beta, so far, with strong uptake in usage. The back end is powered by our partner, Photon Health.
目前已有超過 1,000 名開立處方者參與我們的 beta 測試,使用率成長強勁。後端由我們的合作夥伴 Photon Health 提供支援。
Okay. Now, to AI monetization, which is an important part of today's call, having grown our AI Search footprint so much over the last year, we're ready to monetize against our clients' large paid-search budgets.
好的。接下來談 AI 變現,這是今天電話會議的重要部分。過去一年我們大幅擴張 AI Search 的覆蓋範圍後,我們已準備好針對客戶龐大的付費搜尋預算進行變現。
We launched at our annual Pharma Client Summit in New York last week, with 40 marketing leaders from the world's largest pharma companies in attendance. Their response was enthusiastic, particularly around using our [AI Search Surface] to reach prescribers in the exact moments they're researching options, something traditional paid search can't do.
我們上週在紐約舉辦的年度 Pharma Client Summit 正式推出,現場有來自全球最大藥廠的 40 位行銷領導者出席。他們反應熱烈,特別看好使用我們的 [AI Search Surface] 在處方者正好研究治療選項的關鍵時刻觸及他們,這是傳統付費搜尋做不到的。
We've already closed our first few AI search deals with top 20 pharma manufacturers. But these are early innings in a nascent and regulated market. Our financial guidance reflects that.
我們已經與前 20 大藥品製造商中的幾家完成首批 AI 搜尋交易。但在一個新興且受監管的市場中,這仍處於非常早期的階段。我們的財務指引也反映了這一點。
We've forecasted minimal AI revenue contribution this fiscal year, while allowing for a wider range of AI investments and related expenses -- meaning, higher R&D, compute, and marketing spend that will weigh on near-term margins. We think that's the right trade.
我們預估本會計年度 AI 營收貢獻將相當有限,同時也預留更寬的 AI 投資與相關費用區間——也就是更高的研發、運算與行銷支出,將對短期利潤率造成壓力。我們認為這樣的取捨是正確的。
Longer-term, we believe AI Search alone represents a multibillion-dollar new TAM, on top of the existing pharma marketing budgets we serve today. To put it plainly: We paid $63 million for Pathway AI last summer. Now, we're spending against the opportunity it unlocked. This is our AI investment year.
從較長期來看,我們相信僅 AI Search 就代表一個數十億美元規模的全新 TAM,且是在我們目前所服務的既有製藥行銷預算之上。簡單說:我們去年夏天以 6,300 萬美元收購了 Pathway AI。現在,我們正針對它所解鎖的機會加大投入。今年是我們的 AI 投資年。
Finally, two management updates:
最後,兩項管理層更新:
As we announced last month, Anna Bryson made the difficult decision to step down as CFO, after being on medical leave. We all miss her and wish her the very best.
如同我們上個月宣布的,Anna Bryson 在醫療休假後做出艱難決定,卸任 CFO。我們都很想念她,並祝福她一切順利。
Today, we're pleased to announce Matt Sonefeldt as our new CFO. Over a 25-year career, Matt has led IR, finance, and strategy at LinkedIn; Atlassian; and, most recently, Docusign.
今天,我們很高興宣布 Matt Sonefeldt 出任我們的新任 CFO。在 25 年的職涯中,Matt 曾在 LinkedIn、Atlassian,以及最近的 Docusign 領導投資人關係(IR)、財務與策略工作。
He began on the buy-side at Capital Research, giving him a long-term perspective across tech. Matt has advised us externally for over a year so we know him well. He's a strong operator; a great cultural fit. He joins us in our San Francisco office full-time in early June.
他在 Capital Research 從買方起步,讓他對整體科技產業具備長期視角。Matt 過去一年多以外部顧問身分協助我們,因此我們對他很熟悉。他是很強的營運者,也非常契合我們的文化。他將於 6 月初起在我們舊金山辦公室全職加入。
We're also pleased to welcome Dr. Steve Zatz as our new President. A Cornell-, Yale-, and Harvard-trained physician, Steve spent 20 years at WebMD, Medscape, with the last seven as President and CEO. We've admired Steve's work from the other side of the field for years.
我們也很高興歡迎 Steve Zatz 醫師出任我們的新任總裁。Steve 是受訓於康乃爾、耶魯與哈佛的醫師,曾在 WebMD、Medscape 任職 20 年,最後 7 年擔任總裁兼執行長。多年來,我們一直在場上另一端欣賞 Steve 的工作。
He's advised us over the past five months. It's been great to have him on our side. He's based near New York City and brings deep, longstanding relationships across the industry.
過去五個月他一直在為我們提供建議。有他站在我們這一邊非常棒。他常駐紐約市附近,並在整個產業中擁有深厚且長期的關係。
To close, we've long been the largest US physician network. This year, we're becoming the largest physician AI platform.
總結來說,我們長期以來一直是美國最大的醫師網路。今年,我們正成為最大的醫師 AI 平台。
It's a multibillion-dollar opportunity. We have the team, the tools, and the trust to win. That's the company we're investing to build this year.
這是一個數十億美元的機會。我們擁有團隊、工具與信任來贏得勝利。這就是我們今年要投資打造的公司。
Thank you to my Doximity teammates, who continue to work incredibly hard to care for those who care for us.
感謝我的 Doximity 團隊夥伴,你們持續非常努力地工作,照顧那些照顧我們的人。
With that, I'll hand it over to our VP of Investor Relations, Perry Gold. Perry?
接下來,我把時間交給我們的投資人關係副總裁 Perry Gold。Perry?
Perry Gold - Vice President - Investor Relations
Perry Gold - Vice President - Investor Relations
Thanks, Jeff. Thanks to everyone on the call today.
謝謝你,Jeff。也謝謝今天參與電話會議的各位。
Fourth-quarter revenue grew to $145 million, up 5% year over year, exceeding the high end of our guidance range. Full-year revenue grew to $645 million, up 13%, year over year. Our existing customers continue to lead our growth.
第四季營收成長至 1.45 億美元,年增 5%,並超越我們財測區間的上緣。全年營收成長至 6.45 億美元,年增 13%。我們的既有客戶持續引領我們的成長。
We finished the quarter with a net-revenue retention rate of 109% on a trailing 12-month basis. Our top 20 customers remained our fastest growing, with a net-revenue retention rate of 114%.
以過去 12 個月(TTM)計算,我們本季的淨營收留存率為 109%。我們前 20 大客戶仍是成長最快的族群,淨營收留存率為 114%。
We ended the quarter with 125 customers contributing at least $500,000 each in subscription-based revenue on a trailing 12-month basis. This is a roughly 6% increase from the 118 customers that we had in this cohort a year ago. These customers accounted for 83% of our total revenue.
本季結束時,以過去 12 個月(TTM)計算,共有 125 位客戶各自貢獻至少 50 萬美元的訂閱式營收。相較一年前同一族群的 118 位客戶,約增加 6%。這些客戶占我們總營收的 83%。
Turning to our profitability, non-GAAP gross margin in the fourth quarter was 89% versus 91% in the prior-year period, driven by AI compute costs. For the full fiscal year, non-GAAP gross margin was 91% versus 92%, last year.
接著看獲利能力,第四季非 GAAP 毛利率為 89%,相較去年同期的 91% 下滑,主要受 AI 運算成本驅動。就全年而言,非 GAAP 毛利率為 91%,相較去年的 92%。
Adjusted EBITDA for the fourth quarter was $66 million and adjusted EBITDA margin was 45% compared to $70 million and a 50% margin in the prior-year period.
第四季調整後 EBITDA 為 6,600 萬美元,調整後 EBITDA 利潤率為 45%;相較去年同期為 7,000 萬美元與 50% 利潤率。
The primary driver for the change in EBITDA margin versus last year is our increased investment in AI compute, driven by a steep ramp in AI usage, which is outgrowing overall workflow engagement. We will continue this investment into fiscal 2027; and are excited about the engagement and commercial potential ahead.
相較去年 EBITDA 利潤率變動的主要原因,是我們增加對 AI 運算的投資;這是由於 AI 使用量快速攀升,其成長速度超過整體工作流程的互動參與。我們將把這項投資延續至 2027 會計年度;並對未來的互動參與與商業潛力感到振奮。
For the full fiscal year, adjusted EBITDA was $358 million and adjusted EBITDA margin was 55% compared to $314 million and a 55% margin last year.
就全年而言,調整後 EBITDA 為 3.58 億美元,調整後 EBITDA 利潤率為 55%;相較去年為 3.14 億美元與 55% 利潤率。
We are proud to continue to run a highly profitable business, with 14% year-over-year growth in our bottom line.
我們很自豪能持續經營一個高獲利的業務,底線(淨利)年增 14%。
Now, turning to our balance sheet, cash flow, and an update on our share repurchase program.
接下來談資產負債表、現金流,以及我們股票回購計畫的最新進展。
We generated free cash flow in the fourth quarter of $107 million compared to $97 million in the prior-year period, an increase of 11%, year over year. For the full fiscal year, we generated free cash flow of $317 million compared to $267 million last year, representing growth of 19%, year on year.
第四季我們產生自由現金流 1.07 億美元,相較去年同期的 9,700 萬美元,年增 11%。就全年而言,我們產生自由現金流 3.17 億美元,相較去年的 2.67 億美元,年增 19%。
In addition, free cash flow was 49% of revenue for fiscal 2026.
此外,2026 會計年度自由現金流占營收比重為 49%。
We ended the year with $749 million of cash, cash equivalents, and marketable securities.
年底我們持有 7.49 億美元的現金、約當現金與有價證券。
During the fourth quarter, we repurchased $91 million of our shares, bringing the total value of shares bought back in fiscal 2026 to $432 million, a significant step-up versus the $116 million repurchase in fiscal 2025.
第四季期間,我們回購了 9,100 萬美元的股票,使 2026 會計年度累計回購金額達到 4.32 億美元,較 2025 會計年度的 1.16 億美元回購大幅提升。
As of March 31, we had $493 million remaining in our existing repurchase program.
截至 3 月 31 日,我們在既有回購計畫中仍有 4.93 億美元的額度可用。
Now, moving on to our outlook, for the first fiscal quarter of 2027, we expect a revenue range of $151 million to $152 million, representing 4% growth at the midpoint. We expect adjusted EBITDA in the range of $68.5 million to $69.5 million, representing a 46% adjusted EBITDA margin.
接著看展望,對於 2027 會計年度第一季,我們預期營收區間為 1.51 億至 1.52 億美元,以中位數計算成長 4%。我們預期調整後 EBITDA 區間為 6,850 萬至 6,950 萬美元,對應 46% 的調整後 EBITDA 利潤率。
For the full fiscal year, we expect revenue in the range of $664 million to $676 million, representing 4% growth at the midpoint. We expect adjusted EBITDA in the range of $323 million to $335 million, representing a 49% adjusted EBITDA margin.
對於全年,我們預期營收區間為 6.64 億至 6.76 億美元,以中位數計算成長 4%。我們預期調整後 EBITDA 區間為 3.23 億至 3.35 億美元,對應 49% 的調整後 EBITDA 利潤率。
Additionally, we expect stock-based comp to increase to the low-[20%s] as a percent of revenue in fiscal 2027 and then, trend back down, starting in 2028. This is primarily the result of our Pathway acquisition, as well as performance-based grants issued in fiscal 2026 for our growing AI team.
此外,我們預期 2027 會計年度的股票基礎薪酬(stock-based comp)占營收比重將上升至 20% 出頭,之後自 2028 年起趨勢回落。這主要是 Pathway 收購案的影響,以及我們在 2026 會計年度針對成長中的 AI 團隊所發放的績效型獎勵。
That said, we expect dilution from these new awards to be more than offset by our share repurchases this year.
即便如此,我們預期這些新獎勵所造成的稀釋,將在今年被我們的股票回購所大幅抵銷,且抵銷幅度更大。
Now, I'll provide more color on our outlook. We are witnessing a continuation of the trend discussed on our last call, with short-term demand in the HCP digital pharma ad market soft and visibility still limited.
接下來,我會對展望提供更多說明。我們看到上次電話會議所討論的趨勢仍在延續:HCP(醫療專業人員)數位製藥廣告市場的短期需求偏弱,能見度仍然有限。
This market environment is a result of policy uncertainty remaining elevated and increased macro risk. Taken together, we expect overall market growth to be modest this year, likely at or below 5%.
這樣的市場環境源於政策不確定性仍處高檔,以及總體風險上升。綜合而言,我們預期今年整體市場成長將較為溫和,可能在 5% 或以下。
Consistent with broader industry trends, many brands still made meaningful upfront investments but with more modest growth and shorter planning horizons than typical.
與更廣泛的產業趨勢一致,許多品牌仍進行了具規模的前期投入,但成長更溫和,且規劃期較以往更短。
As a result, we currently have 65% of our subscription-based revenue guidance booked at this point, in line with our three-year average; however, with more moderate growth incorporated into our guide than prior years.
因此,以目前時點來看,我們的訂閱式營收財測中已有 65% 完成簽訂(booked),與我們三年平均一致;不過,相較過往年度,我們在指引中納入了更溫和的成長假設。
We're encouraged to see second-half budget activity beginning to materialize from several brands that were initially more cautious during the upfront. That said, shorter-term spend commitments remain the norm across supplemental buys at a number of other brands.
我們很高興看到,原本在前期採購(upfront)期間較為審慎的幾個品牌,其下半年預算活動已開始逐步顯現。不過,在其他多個品牌的補充採買中,較短期的支出承諾仍然是常態。
Within this environment, the dynamic we're seeing is relatively consistent. There isn't much incremental budget available today. When dollars do free up, brand managers are typically looking for one of two things: innovative new offerings or low-cost engagement options.
在這樣的環境下,我們觀察到的動態相對一致。目前可用的新增預算不多。一旦有資金釋出,品牌經理通常會尋求兩件事之一:創新的新產品/方案,或低成本的互動參與選項。
In many ways, this feels very similar to what we experienced during the early days of HCP-focused programmatic advertising three years ago.
在許多方面,這感覺非常類似於我們三年前在以 HCP(醫療專業人員)為核心的程式化廣告早期所經歷的情況。
We believe we are now well positioned to meet the demand for innovation with the recent launch of our commercial AI Search offering, which is already generating strong early interest and allows us to tap into innovation-focused budgets.
我們相信,隨著近期推出商業 AI Search 產品,我們已具備良好條件來滿足市場對創新的需求;該產品已在早期引發強勁興趣,並使我們得以切入以創新為導向的預算。
We began selling the product in late April. While we do not expect meaningful contribution in the first half of the fiscal year, we do anticipate a more notable ramp, as we move into our fiscal back half.
我們在 4 月下旬開始銷售該產品。雖然我們不預期在本財年上半年會有顯著貢獻,但我們確實預期,隨著進入本財年下半年,成長動能將更為明顯。
We were deliberate in how we built our AI monetization to be aligned with our physician-first commitment. This focused approach has consistently proven to be a long-term winner.
我們在打造 AI 變現模式時採取審慎作法,以確保與我們「醫師優先」的承諾一致。這種聚焦的策略一再證明是長期致勝之道。
Importantly, comparing our business to three years ago, our revenue and engagement are both up more than 50%. As a result, we believe we remain well positioned to outgrow the market, over time.
重要的是,與三年前相比,我們的營收與互動參與度都成長超過 50%。因此,我們相信,隨著時間推移,我們仍具備優於市場成長的良好條件。
Stepping back, despite the near-term market pressure, our underlying fundamentals remain strong. Engagement is at record levels. Product velocity remains high.
退一步看,儘管短期市場承壓,我們的基本面依然強勁。互動參與度創下歷史新高。產品推進速度仍然很快。
We continue to strengthen our AI differentiation through PeerCheck, our integrated platform approach, and our expanding health system distribution footprint.
我們持續透過 PeerCheck、我們的整合式平台策略,以及不斷擴大的醫療體系(health system)分銷/觸達版圖,強化我們在 AI 方面的差異化。
From a profitability standpoint, we remain committed to maintaining adjusted EBITDA margins in the high-[40%s] or better in fiscal 2027, even as we continue to invest in [AI Compute] and PeerCheck; and increase our brand marketing spend.
就獲利能力而言,我們仍致力於在 2027 財年維持調整後 EBITDA 利潤率在 40% 高段或更高,即便我們持續投資於 [AI Compute] 與 PeerCheck,並提高品牌行銷支出亦然。
As Jeff mentioned, workflow active provider growth accelerated to approximately 30% year over year, with AI engagement growing even faster, reinforcing that our tools are becoming increasingly embedded in everyday clinical care.
如 Jeff 所提到,工作流程(workflow)活躍提供者(active provider)成長加速至約年增 30%,而 AI 互動參與度成長更快,進一步印證我們的工具正愈來愈深度嵌入日常臨床照護。
We believe we are well positioned to capture a significant share of this emerging growth factor, while continuing to deliver strong profitability.
我們相信,我們具備良好條件在這項新興成長動能中取得可觀市占,同時持續交出強勁的獲利表現。
As always, we remain focused on the long-term by investing to expand our platform's clinical care capabilities; and delivering strong and measurable ROI for our customers.
一如既往,我們仍以長期為重點,透過投資擴展平台的臨床照護能力,並為客戶提供強勁且可衡量的投資報酬率(ROI)。
We believe we're still early in a multi-year shift toward AI-driven healthcare workflows. We're excited about the opportunity ahead.
我們相信,我們仍處於邁向 AI 驅動醫療工作流程的多年轉變的早期階段。我們對前方的機會感到振奮。
With that, I will turn it over to the operator for questions.
接下來,我把時間交給接線員進行提問。
Operator
Operator
Thank you. We'll now begin the question-and-answer session.
謝謝。我們現在開始問答環節。
(Operator Instructions)
(接線員指示)
Brian Peterson, Raymond James.
Brian Peterson,Raymond James。
Brian Peterson - Equity Analyst
Brian Peterson - Equity Analyst
Thanks for taking the question, guys.
謝謝讓我提問,各位。
Jeff, I wanted to start on the AI Search launch. It's great to see a large customer win.
Jeff,我想先從 AI Search 的發布談起。很高興看到拿下一位大型客戶。
Given that you've seen a few innovation cycles in pharma over the years, I'm just curious, how should we be thinking about the appetite for customers to invest in AI solutions? As we're thinking about a maybe two to three-year roadmap, any sense for how big these AI products could be over that timeframe?
鑑於你多年來在製藥業看過幾個創新週期,我想請教,我們應該如何看待客戶投資 AI 解決方案的意願?在我們思考可能兩到三年的產品路線圖時,你對這些 AI 產品在該期間內可能做到多大規模,有沒有一些看法?
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Thanks, Brian. This is Jeff.
謝謝你,Brian。我是 Jeff。
Yes. Having just come back from New York, last week, where we were with 40 of these top pharmaceutical marketing executives, I was surprised, honestly, by the degree to which they are really all leaned in on AI.
是的。我上週剛從紐約回來,當時我們與 40 位頂尖的製藥行銷高階主管在一起;老實說,我對他們全力投入 AI 的程度感到驚訝。
In fact, a number of the top 20 pharma reported to us that they have minimum budget percentages -- 10%, 20% of their budgets -- that, from a top-down perspective, are part of their compensation plan that they should be spending on AI.
事實上,前 20 大藥廠中有不少向我們表示,他們有最低預算比例——例如 10%、20% 的預算——從上而下的角度來看,這是其薪酬計畫的一部分,要求他們必須把這些預算花在 AI 上。
We are happy to offer them an AI product now that we've spent the first year, post-Pathway acquisition, here, focusing on physicians first, which we always do; and building a better, more accurate product, with peer review, with the built-in drug reference, with over 10,000 cited authors reviewing the results, and winning 2:1 in head-to-head studies with residents.
我們很高興現在能提供他們一項 AI 產品;在完成 Pathway 併購後的第一年,我們把重心放在醫師優先——這一直是我們的做法——並打造更好、更精準的產品,具備同儕審查、內建藥物參考資料、超過 10,000 位引用作者審閱結果,且在與住院醫師的正面對決研究中以 2:1 勝出。
But I'll tell you: The pharma interest in all of this is quite high. It provides a lot of insight to them, in addition to the -- being there at the place of learning and decision-making.
但我可以告訴你:藥廠對這一切的興趣相當高。除了——在學習與決策的場域中出現——之外,這也能為他們提供大量洞察。
They're understanding gaps, frankly, in their own products' marketing, which is really interesting. Again, we're excited to have a whole day to spend with them talking about how we can help them with that.
他們正在理解坦白說其自家產品行銷中的缺口,這非常有意思。再次強調,我們很期待能花一整天與他們討論我們如何協助他們做到這點。
In terms of the TAM, we do think it's a multibillion-dollar TAM, as we said in the prepared remarks. If you look at how much US pharma spent on paid search in all -- and it's hard to know because it's -- you have to piece together some e-marketer data with some Google data -- but it's probably around $19 billion in overall US paid search.
就 TAM(總可服務市場)而言,我們確實認為這是一個數十億美元規模的 TAM,正如我們在事先準備的講稿中所說。如果你看美國藥廠在付費搜尋(paid search)上的總支出——而這很難精確掌握,因為你必須把一些 eMarketer 的資料與部分 Google 的資料拼湊起來——但整體美國付費搜尋可能約為 190 億美元。
Now, a lot of that's for consumers. That's why we're saying multi-billion dollar for healthcare professionals.
當然,其中很大一部分是面向消費者。這也是為什麼我們說,針對醫療專業人員(HCP)的市場是數十億美元規模。
But we think it's a very large market. It is incremental to the market we're in today. Today, we're not considered to be part of the paid-search market. And so we're excited to be entering that market, just last week.
但我們認為這是一個非常大的市場。而且它是我們目前所在市場之外的增量機會。目前,我們並不被視為付費搜尋市場的一部分。因此,我們很興奮能在上週正式進入這個市場。
Brian Peterson - Equity Analyst
Brian Peterson - Equity Analyst
Great. I appreciate the color, Jeff. Maybe just a follow-up on the budgets for calendar year '26:
很好。Jeff,謝謝你提供的補充說明。我想再追問一下 2026 曆年預算:
I appreciate that it's a fluid environment. But are you seeing significant changes in how customers are buying, just, the shorter-term commitments? I'd love to understand how you guys are thinking about maybe mid-year buying and end-of-year buying that underpins that 4% growth for the year.
我理解這是個變動的環境。但你們是否看到客戶的採購方式出現顯著變化,例如更偏向短期承諾?我想了解你們如何看待年中採購與年底採購,這些如何支撐全年 4% 的成長。
Thanks, guys.
謝謝各位。
Perry Gold - Vice President - Investor Relations
Perry Gold - Vice President - Investor Relations
Hey, Brian. It's Perry. How are you?
嗨,Brian。我是 Perry。你好嗎?
Yeah. It's a great question. There's noticeable differences this year. I think the overarching theme is there's more uncertainty: policy and, now, macro.
是的。這是個很好的問題。今年確實有明顯差異。我認為整體主軸是:不確定性更高——政策面,以及現在的總體經濟。
I think, as a result, a lot of these companies; a lot of the C-suite want to retain optionality. And so we're seeing some of these incremental buys are just shorter duration. That's, like, a consistent theme that's come up.
我想因此,很多這些公司、很多高層(C-suite)都希望保留選擇權。所以我們看到一些增量採買的期間更短。這是一個反覆出現、相當一致的主題。
That's a big one. I think that's leading to less visibility for us. That's the broader theme.
這是很重要的一點。我認為這也導致我們的能見度降低。這就是更大的整體趨勢。
I think the other thing I'll call out -- and I referenced it in my script -- it feels like, when there is incremental budget, they're looking for innovation, which we now have to offer, where they're looking for the bargain bin. They're looking for some cheaper engagements.
另外我也想補充——我在講稿中有提到——感覺是,當有增量預算時,他們要嘛尋求創新,而我們現在有創新可以提供;要嘛就是在找「特價區」,尋找更便宜的互動方案。他們在找一些成本更低的互動方式。
That's something -- that's a world we've never really played in: more premium offering for positions, native ad formats. We don't play in the banner ad -- cheaper-by-the-pound space.
那是另一回事——那是一個我們過去從未真正涉足的領域:針對特定職位的更高端產品、原生廣告格式。我們不做橫幅廣告——那種按重量計價的低價市場。
I think we can now offer them some of what they're looking for that limited incremental budget they have. There's a lot of excitement around our AI Search offering. But those are the key trends we're seeing, right now.
我認為我們現在可以提供他們正在尋找的一部分,來承接他們那有限的增量預算。市場對我們的 AI 搜尋產品非常興奮。但這些就是我們目前看到的關鍵趨勢。
Operator
Operator
Michael Cherney, Leerink Partners.
Michael Cherney,Leerink Partners。
Michael Cherny - Equity Analyst
Michael Cherny - Equity Analyst
Good evening; afternoon. Thanks for taking the question.
晚上好;下午好。謝謝讓我提問。
Maybe if I can jump in on the AI thought process a bit: You mentioned in the script -- you talked about the dynamics of offering innovation. I appreciate all the components you have in place.
也許我可以就 AI 的思考脈絡再深入一點:你在講稿中提到——談到了提供創新的動態。我很欣賞你們已經具備的所有組成要素。
That being said, obviously, it's a competitive market. There's a lot of investment being made for [Dr. Eyeballs], as you see it.
話雖如此,顯然這是一個競爭激烈的市場。如你所見,為了「[Dr. Eyeballs]」正投入大量資金。
As you think about the incremental investment being on compute spend, or other R&D spend, or people, how are you best measuring yourself to make sure that this amount of spend you have this year is the right amount to further kick off and expand your AI journey?
當你思考增量投資是放在運算支出、其他研發支出,或人力上時,你們如何最好地衡量自己,以確保今年這個支出水準是正確的,能進一步啟動並擴展你們的 AI 旅程?
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
This is Jeff. I can take that. Thanks, Michael. It's a good question.
我是 Jeff。我可以回答這題。謝謝你,Michael。這是個好問題。
The reality is the amount we're spending on compute is going up dramatically. That's a good thing.
現實是,我們在運算上的花費正在大幅上升。這是件好事。
Honestly, we're helping more doctors answer more questions; take more notes than ever before. That's probably the number 1 metric we have for ourselves and we'll have for ourselves this year -- is continuing to grow our our AI usage among doctors.
坦白說,我們正在幫助更多醫師回答更多問題;做比以往更多的筆記。這大概是我們對自己最重要的第 1 項指標,而且今年也會持續如此——也就是持續提升醫師對我們 AI 的使用。
We want to be the physician's private AI assistant. I think we are well positioned to be that today.
我們希望成為醫師的私人 AI 助理。我認為我們今天已經具備很好的條件做到這一點。
I'm really proud. We grew 30% year on year in our workflow usage. It's the biggest jump we've ever had from: 720,000 to 800,000 quarterly active prescribers.
我真的很自豪。我們的工作流程使用量年增 30%。這是我們歷來最大的跳升:季度活躍開立處方者從 72 萬成長到 80 萬。
To put that in perspective: Three years ago -- fiscal '24 -- and we've grown our engagement 50% since fiscal '24 so from fiscal '24 to fiscal '26, we've grown our revenue 50% or more in that same period.
換個角度來看:三年前——2024 財年——而且自 2024 財年至今我們的互動度成長了 50%,也就是從 2024 財年到 2026 財年,在同一期間我們的營收也成長了 50% 或更多。
We've grown our free cash flow per share more than 2x during that period. I think the AI opportunity that lies in front of us now is similar to what we've had this last few years.
在那段期間,我們的每股自由現金流成長超過 2 倍。我認為現在擺在我們面前的 AI 機會,與過去這幾年我們所面對的機會相似。
We're excited to lean in and invest here. A lot of it is competing. But a lot of it's also getting out with doctors; having them do the peer review; making sure that we continue to put the most accurate product out there on the market.
我們很期待加大投入並在這裡投資。其中很大一部分是競爭使然。但也有很大一部分是走到醫師身邊;讓他們進行同儕審查;確保我們持續把市場上最準確的產品推出去。
Because, if you ask doctors what they like about AI, there's a lot of things they'll tell you. We're delivering on those.
因為如果你問醫師他們喜歡 AI 的什麼,他們會告訴你很多點。我們正在把那些做到位。
But the number 1 concern they have: 71% of physicians who've used AI in a 3,000-physician survey that we ran a few months ago, the biggest concern is the accuracy of the AI.
但他們最大的第 1 項疑慮是:在我們幾個月前做的一項涵蓋 3,000 名醫師、且曾使用過 AI 的調查中,有 71% 的醫師表示,最大的擔憂是 AI 的準確性。
The reality is, if you just hit the refresh button, you'll get a different answer. That's not very comforting for someone who's putting their license on the line and making a very high-stakes decision for a patient.
現實是,你只要按一下重新整理,就會得到不同的答案。對於一個必須承擔執照風險、並為病患做出高風險決策的人來說,這並不令人安心。
And so that's where our investment in having cited authors, physicians who are experts in the field, do peer reviews; add practice pearls; make sure that the answers are correct, we think is a big, great, long-term investment, alongside the AI investments.
因此,我們在投資上會讓具引用來源的作者、也就是該領域的專家醫師,來做同儕審查;補充臨床實務要點;確保答案正確。我們認為這是一項重大、很棒的長期投資,並與 AI 投資並行。
Michael Cherny - Equity Analyst
Michael Cherny - Equity Analyst
Got it. I'm good for now. Thanks.
了解。我目前就到這裡。謝謝。
Operator
Operator
Glenn Santangelo, Barclays.
Glenn Santangelo,Barclays。
Glen Santangelo - Equity Analyst
Glen Santangelo - Equity Analyst
Thanks for taking my questions. Just two quick ones for me.
謝謝讓我提問。我這邊只有兩個簡短問題。
Hey, Jeff, I want to talk about the HCP marketing business for a second. You highlighted the continued regulatory concerns.
嗨,Jeff,我想先談一下 HCP 行銷業務。你提到了持續存在的法規疑慮。
Could you elaborate on what those concerns are and how much you think that's impacting the market? Is it coming from [IRA] price reductions? Like, what do you think is really causing the hesitation there?
你能否更詳細說明那些疑慮是什麼,以及你認為這對市場的影響有多大?是來自 [IRA] 的降價嗎?例如,你認為真正造成猶豫的原因是什麼?
And then, secondly, with respect to this new AI, the paid-search offering, I'm just curious, could you give us a sense for maybe how the competitive landscape, maybe, is different here than your traditional HCP marketing business; and maybe what the margin structure might be on that incremental revenue stream?
第二,關於這個新的 AI 付費搜尋產品,我想了解一下:你能否讓我們感受一下,這裡的競爭格局可能與你們傳統的 HCP 行銷業務有何不同;以及這條新增營收來源的毛利結構可能會是什麼樣子?
Thanks so much.
非常感謝。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Great. Thanks, Glenn. I'll answer part of this. I think Perry will jump in here with a bit more.
好的。謝謝你,Glenn。我會回答其中一部分。我想 Perry 也會補充更多。
First, I had the word regulatory in my script -- my prepared remarks -- here. That was referring to our new AI product.
首先,我在講稿——也就是我事先準備的發言——裡用了「法規」這個詞。那指的是我們新的 AI 產品。
What it really boils down to is they're buying keywords but they're also buying suppression words. There's a lot that you have to figure out to make sure that the targeting around keywords is done correctly in a way that we're always proud of the way it appears in front of a physician.
歸根結底,他們買的是關鍵字,但也會買「抑制詞」。你必須釐清很多事情,才能確保圍繞關鍵字的定向是正確的,並且我們始終能對它在醫師面前呈現的方式感到自豪。
Again, we thought long and hard about this. We've tested it with our 160 doctors at our AI Summit we had back here in San Francisco in March.
再次強調,我們對此深思熟慮。我們在 3 月於舊金山舉辦的 AI 高峰會上,已與我們的 160 位醫師進行測試。
Again, I'm very proud that our commercial offering with AI does not slow down the doctor, at all. Others do. Others make you wait and watch an ad. We do not do that. We get you the answer you're looking for as fast as we can.
同樣地,我非常自豪我們結合 AI 的商業化產品完全不會拖慢醫師。其他人會。其他人會讓你等待並觀看一則廣告。我們不會這樣做。我們會以最快速度把你要找的答案提供給你。
Our pharma clients are on board with doing it that way with us. But that does require some regulatory review and testing. And so it's really just why we think the AI revenue would not really be significant until later this fiscal year because, again, of the regulatory needs and reviews.
我們的製藥客戶也同意與我們用這種方式來做。但這確實需要一些法規審查與測試。因此,這也是為什麼我們認為 AI 營收要到本財年稍晚才會真正顯著,原因就在於法規需求與審查。
Beyond that, the regulatory environment hasn't changed a whole lot. Obviously, we have FDA changes and lots of things happening.
除此之外,法規環境並沒有太大的改變。當然,我們也看到 FDA 的變動以及許多事情正在發生。
It's a more turbulent environment, just generally. That does lead to a bit of macro, I'd say, concern [malaise]. Keep in mind: Most of our clients are European companies, right? If you look at the top 20 pharma, this is a European-based group.
整體而言,這是一個更動盪的環境。我想這確實會帶來一些總體層面的擔憂[低迷]。請記住:我們的大多數客戶是歐洲公司,對吧?如果你看前 20 大藥廠,這是一個以歐洲為主的群體。
But we continue to do very well, again, in working with them and their regulatory teams; and continuing to show them ROI, which, in the end, is really the most important thing.
但我們仍然做得很好,持續與他們及其法規團隊合作;並持續向他們展示投資報酬率(ROI),而這在最後才是真正最重要的。
Perry Gold - Vice President - Investor Relations
Perry Gold - Vice President - Investor Relations
Hey, Glenn. I'll just add a little to what Jeff said:
嗨,Glenn。我再補充 Jeff 所說的一點:
I think, in terms of how this is different than some of our other sales, what we're selling, it's a little different for the first time. Rather than our advertisers looking to target certain HCPs, we're selling them conditions, which is a basket of keywords.
我認為,就這與我們其他一些銷售有何不同而言,我們這次所賣的東西第一次有點不一樣。與其讓廣告主想要鎖定特定的 HCP,我們賣給他們的是「病症」,也就是一籃子的關鍵字。
The product itself is more than just a native ad unit, it's a package. It (technical difficulty) -- delivers insights. It delivers some retargeting capabilities, which makes our other products -- the value of those products -- go up.
這個產品本身不僅僅是一個原生廣告單元,而是一個套裝方案。它(技術難度)——能提供洞察。它也提供一些再行銷能力,這會讓我們其他產品——那些產品的價值——提升。
There's better signal that's being brought in. There's better intent being brought in. It is a bit of a different sale.
帶進來的訊號更好。帶進來的意圖更強。這在銷售上有點不一樣。
To Jeff's point, it is a little bit of a different regulatory approval process. It'll take a little longer to get these things up and running for the first time.
呼應 Jeff 的觀點,這在法規核准流程上也有點不同。第一次把這些東西建置並跑起來,會需要更久一點。
But I think it's incredibly additive and accretive to the entire product portfolio. We're really excited to be out selling this new product.
但我認為它對整體產品組合而言是非常有加成、且具增益性的。我們非常興奮能在外部銷售這個新產品。
Glen Santangelo - Equity Analyst
Glen Santangelo - Equity Analyst
Okay. Thank you.
好的。謝謝。
Operator
Operator
Elizabeth Anderson, Evercore ISI.
Elizabeth Anderson,Evercore ISI。
Elizabeth Anderson - Analyst
Elizabeth Anderson - Analyst
Hi, guys. Thanks so much for the question.
嗨,各位。非常感謝讓我提問。
I was wondering if you could talk a little bit more -- it's a two-parter -- just about how you envision the gross -- sorry -- the margin structure for fiscal '27.
我想請你們再多談一點——這是兩個部分——關於你們如何看待 2027 會計年度的毛利——抱歉——的利潤率結構。
Should it be, given some of those AI investments and the AI computing costs, similar to what we saw in the fourth quarter? Is that the right way to think about it? Just help us parse apart maybe some of those gross margin versus OpEx investments.
考量到一些 AI 投資以及 AI 運算成本,它是否會與我們在第四季看到的情況相近?這樣理解對嗎?也請協助我們拆解一下,可能哪些是毛利率端、哪些是營運費用(OpEx)端的投資。
And then, secondarily, can you go into a little bit more detail about the new CFO? What -- obviously, we saw his experience but just any other traits that you thought would be helpful for the business, as you enter into this new era.
另外,第二個問題,能否再多提供一些新任 CFO 的細節?我們當然看到了他的經歷,但還有沒有其他你們認為在公司進入這個新時代時,對業務會有幫助的特質?
Thank you.
謝謝。
Perry Gold - Vice President - Investor Relations
Perry Gold - Vice President - Investor Relations
Hey, Elizabeth. Yeah. I can take the margin question, first.
嗨,Elizabeth。好的。我先回答利潤率的問題。
I think the key things to look out for in fiscal '27:
我認為 2027 會計年度需要關注的重點是:
For gross margin, I think the big step-up will be AI Compute. That's largely driven by a big jump in engagement.
在毛利率方面,我認為最大的上升項會是 AI 運算(Compute)。這主要是由互動參與度的大幅提升所驅動。
The other piece, to a lesser extent, there's a lot of licensing costs for journals for docs. But that's a much lower piece of it.
另外一塊影響較小的是,針對醫師使用的期刊會有不少授權成本。但那占比要小得多。
For the rest of OpEx, you now have a team that just got leveled. There's -- the expense base going up a little bit. We have a few more AI engineers. You've got a full run rate of that spend this year.
至於其他營運費用(OpEx),你現在有一個剛完成調整的團隊。費用基礎會小幅上升。我們多了幾位 AI 工程師。今年會反映這些支出的完整年化水準。
We've got some PeerCheck investments that hit selling and marketing.
我們也有一些 PeerCheck 的投資會落在銷售與行銷。
This year, I think, for the first time, we're really leaning into brand marketing. I think our product velocity is so high. There's so many new incredible AI features we're rolling out. We really want to go out and make some noise around that and educate our physicians about it.
我想今年是第一次,我們真的加大品牌行銷的力道。我認為我們的產品迭代速度非常快。我們正在推出非常多令人驚豔的新 AI 功能。我們很希望能對外製造一些聲量,並教育我們的醫師用戶了解這些。
And so I think that's an online presence; that's a conference presence. We have a team, internally, that's very focused on this now.
因此我認為這會包含線上曝光;也包含在會議上的曝光。我們內部現在有一個團隊非常專注在這件事上。
And so I think that's an intentional investment that's a little different than what you've seen from us in the past. We think it's a really good use of funds, right now.
所以我認為這是一項有意識的投資,跟你們過去看到我們做的有點不同。我們認為在目前這個時間點,這是資金的很好用途。
I will pass the next question to Jeff. I'll just say I've known Matt for many years from my time covering LinkedIn on the sell-side. Matt's fantastic. I'm thrilled to have him here.
接下來我把下一個問題交給 Jeff。我只想說,我從以前在賣方研究端覆蓋 LinkedIn 的時候就認識 Matt 很多年了。Matt 非常出色。我很高興他加入我們。
But I'll let Jeff take the rest of that.
但其餘部分我讓 Jeff 來回答。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Yeah. I'm excited to introduce Matt, who's sitting right next to me here.
是的。我很高興介紹 Matt,他就坐在我旁邊。
I'll just say that we worked with Matt for over a year as a consultant. He has just really been super helpful.
我先說,我們以顧問的身分與 Matt 合作超過一年。他真的幫了非常大的忙。
I feel like a lot of the team already knew him. When we started talking about who we would like and the types of attributes we'd like in a CFO leadership role here, Matt just checked all the boxes.
我覺得團隊裡很多人其實早就認識他。當我們開始討論想要找誰、以及我們希望 CFO 領導角色具備哪些特質時,Matt 幾乎把所有條件都符合了。
In particular, his experience is very relevant for us. I think the way that LinkedIn has, I think, been very professional but also high-growth; and built a marketing solutions business, in particular, using a portal -- he helped inform a lot of that portal strategy for us a couple of years ago. That continues to do well.
尤其是,他的經驗對我們非常相關。我認為 LinkedIn 一方面非常專業、另一方面又是高成長;並且建立了行銷解決方案業務,特別是透過入口網站(portal)——他在幾年前就協助我們形成了很多 portal 策略。而那也持續表現得很好。
If we don't get a chance to say later: We have doubled the number of portal users that we have, year on year. The portal is a perfect place to deploy more AI insights and more of the search-bidding and other things that Perry just talked about a moment ago.
如果後面沒有機會再提:我們的 portal 使用者數量年對年已經翻倍。portal 是部署更多 AI 洞察、以及更多搜尋競價與 Perry 剛剛提到的其他功能的絕佳場域。
Matt's been not only, I think, a great leader here but, also, someone who's brought a lot of industry expertise.
Matt 不僅是我認為在這裡很棒的領導者,也帶來了大量的產業專業。
With that, Matt?
那麼,Matt?
Matt Sonefeldt - Chief Financial Officer
Matt Sonefeldt - Chief Financial Officer
Thank you, Elizabeth, for the question.
謝謝你,Elizabeth,提出這個問題。
I am incredibly excited to be here, I think, for a lot of different reasons.
我非常興奮能來到這裡,我想原因有很多。
I think, when I look at Doximity, I see it as a company that has just incredible platform potential along the ways of other companies that I've been privileged to be a part of, like LinkedIn; like Atlassian, an incredible brand; like Docusign.
我認為,當我看 Doximity 時,我把它視為一家具備驚人平台潛力的公司,類似於我有幸參與過的其他公司,例如 LinkedIn;例如 Atlassian(非常強的品牌);例如 Docusign。
For us, some of our assets are just the largest medical professional digital network, 800,000 workflow users -- just to say that again, with engagement that's accelerating behind a lot of the AI innovation that we're doing, right now; and incredible monetization machine that's grown over multiple cycles, building on that strong engagement and relationship with medical professionals, as well.
對我們而言,我們的一些資產包括:最大的醫療專業人士數位網路、80 萬名工作流程使用者——再說一次——而且在我們目前所做的大量 AI 創新帶動下,互動參與度正在加速;同時也有一個非常強的變現引擎,歷經多個週期成長,建立在這種強勁的參與度以及與醫療專業人士的關係之上。
It's underpinned by the relationship we have across health systems. I think when you look at, I think, the innovation that Doximity is investing in and creating, right now, it can -- our pharma ad business, in particular -- really evolve from here into that search ad market.
這一切的基礎,是我們在各個醫療體系(health systems)之間建立的關係。我認為當你看 Doximity 目前正在投資並創造的創新時,它可以——特別是我們的藥廠廣告業務——從這裡進一步演進到搜尋廣告市場。
That's something that LinkedIn did an incredible job over multiple years with evolving its ad business.
這也是 LinkedIn 在多年之間把其廣告業務演進做得非常出色的一件事。
I think, for me, it's really important to be part of a special culture. Doximity is a special culture.
對我來說,能成為一個特別文化的一部分非常重要。Doximity 就是一個特別的文化。
It thinks about physicians and medical professionals first. It makes investments and big choices focused on the long term. All of that makes it just an incredibly exciting place to be.
它把醫師與醫療專業人士放在第一位。它做投資與重大決策時,聚焦在長期。這些都讓這裡成為一個非常令人興奮的地方。
I can't tell you how pumped I am to get started for this next several years.
我無法形容我對接下來幾年開始投入有多麼期待。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Great. I'll just time in quick and say -- oh, sorry -- that Matt's [blog] was named culture for breakfast, which I love because, of course, culture does eat strategy for breakfast.
很好。我快速補充一下——喔,抱歉——Matt 的[部落格]名稱叫做「culture for breakfast」,我很喜歡,因為當然,文化確實會把策略當早餐吃掉。
The culture here is something that he, yeah, would be a very strong fit for.
這裡的文化是他會非常契合的一點。
Elizabeth Anderson - Analyst
Elizabeth Anderson - Analyst
Awesome. Thank you very much.
太棒了。非常感謝。
Operator
Operator
Ryan MacDonald, Needham & Company.
Ryan MacDonald,Needham & Company。
Ryan MacDonald - Analyst
Ryan MacDonald - Analyst
Thanks for taking my questions.
謝謝讓我提問。
Jeff, as we think about the back half of the year, the mid-year upsells, and year-end budget flush, are you viewing the market opportunity in the demand environment as such that the new AI Search product is really the only opportunity to unlock incremental budget from current levels?
Jeff,當我們思考今年下半年、年中加購(upsells)以及年底預算消化(budget flush)時,你是否認為在需求環境下的市場機會是:新的 AI Search 產品幾乎是唯一能從目前水準解鎖增量預算的機會?
And then, on the pricing side, I know you mentioned that you obviously don't play downmarket, banner ads, and lower priced options but have you looked at or contemplating any pricing changes this year to try to unlock maybe more demand, as we go through into the back half?
然後在定價方面,我知道你提到你們顯然不做下沉市場、不做橫幅廣告以及較低價的選項,但你們今年是否已經看過或正在考慮任何定價調整,以便在進入下半年時釋放更多需求?
Thanks.
謝謝。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Thanks, Ryan. This is Jeff. Perry might help me a bit with this.
謝謝你,Ryan。我是 Jeff。Perry 可能會在這題上幫我補充一下。
I'll just say, yeah, as we get to this year end, we're excited to have an AI product. We did not have an AI product last year end in the bigger part of the budget season. We're excited, too, this year.
我先說一下,是的,隨著我們走到今年年底,我們很興奮能有一個 AI 產品。去年年底在預算季較重要的那段期間,我們還沒有 AI 產品。今年我們也同樣很興奮。
In terms of do we expect growth from our non-AI products, absolutely. The growth that we've seen in our telehealth business -- we had one day this last quarter where we served 720,000 patients. This was during the big snowstorms in the East Coast. No one else is at that scale.
至於我們是否預期非 AI 產品會成長,當然會。我們在遠距醫療業務看到的成長——上個季度有一天我們服務了 72 萬名病患。那是在美國東岸大暴風雪期間。沒有其他人能做到那樣的規模。
Again, as we share, nearly half of all US physicians have an enterprise license to our telehealth service. That is a great opportunity for our clients to have reach because they're waiting millions of minutes during those visits with patients for the patients to fill out their consent forms and do other things.
再重申一次,如同我們分享的,美國幾乎一半的醫師都擁有我們遠距醫療服務的企業授權。這對我們的客戶而言是很好的觸及機會,因為在與病患看診的過程中,病患會花上數百萬分鐘等待、填寫同意書以及做其他事情。
That's a great learning opportunity, right? It's the magic moment. The doctor's there at their desk at home doing their telehealth the day. They're wearing their white lab coat. It's a great moment to learn.
那是一個很棒的學習機會,對吧?那是「魔法時刻」。醫師在家裡的書桌前進行一天的遠距看診。他們穿著白袍。那是很適合學習的時刻。
I don't know if this analogy will fly but I think this is, in a way, like Google, where they have both search and really interesting insights and intent; but then, also YouTube, where you get a lot of time and a lot of attention. I think we brought those two together here.
我不確定這個類比是否貼切,但我覺得某種程度上這有點像 Google:他們同時有搜尋,能提供很有趣的洞察與意圖;同時也有 YouTube,能帶來大量時間與注意力。我認為我們在這裡把這兩者結合起來了。
I actually think the AI product will help us sell more of our existing products because we have a lot of time and attention. Now, we know how, better, to be more relevant.
我其實認為 AI 產品會幫助我們賣出更多既有產品,因為我們擁有大量時間與注意力。現在我們更知道如何提升相關性。
Perry Gold - Vice President - Investor Relations
Perry Gold - Vice President - Investor Relations
Hey, Ryan, it's Perry. I'll just jump in on the pricing question.
Ryan,我是 Perry。我來補充一下定價的問題。
I'd say, high level, we're not changing our pricing model or positioning to compete on cost. The brands that know ROI best are generally not searching for discounts.
我會說,從高層次來看,我們不會改變定價模式或市場定位來以成本競爭。最了解投資報酬率(ROI)的品牌通常不會在找折扣。
I can say, looking back three years ago to the last cycle, these low-cost experiments usually underperform on engagement. Eventually, there's a flight back to quality cycle that plays out over the next, sometimes, a year, a year and a half.
我可以說,回頭看三年前上一個週期,這些低成本的實驗通常在互動表現上不如預期。最後往往會出現回流到高品質的循環,通常在接下來的一年到一年半內發生。
A lot of times, you'll see here that, when (inaudible) -- come back (inaudible) -- going pretty aggressively when some of those lower-cost experiments don't really work out quite as well.
很多時候你會看到,在(聽不清)——回來(聽不清)——當一些低成本實驗效果不如預期時,就會更積極地回到高品質。
I will say, on the AI Search front, it's a bit of a different pricing paradigm. It looks a little different. I think, even versus who we compete within that space, I think we're attractively priced out of the gate.
我會說,在 AI Search 這一端,定價範式有點不同。看起來會不太一樣。我認為即便相較於我們在該領域的競爭對手,我們一開始的定價也相當有吸引力。
I think there's some opportunity there for folks to say, hey, there's good value here. But I think we're not the banner ad company. We're not a cheaper-by-the-pound company.
我覺得那裡有一些機會讓大家覺得:嘿,這裡的價值不錯。但我想我們不是做橫幅廣告的公司。我們也不是那種「按重量算更便宜」的公司。
I think, overall, strategy doesn't really change on the pricing front.
整體而言,我們在定價策略上並沒有真正改變。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Appreciate the color. Thanks.
感謝補充說明。謝謝。
Operator
Operator
Craig Hettenbach, Morgan Stanley.
Morgan Stanley 的 Craig Hettenbach。
Craig Hettenbach - Analyst
Craig Hettenbach - Analyst
Yes. Thank you.
是的。謝謝。
Jeff, on the timeline to monetize DoxGPT, you talked about different medical review. Any parallels to -- if I think back to the point-of-care modules, video modules a couple years ago -- in terms of what you went through there and what you may expect this go-around?
Jeff,關於 DoxGPT 的變現時間表,你提到不同的醫療審查。如果我回想幾年前的臨床照護點(point-of-care)模組、影片模組——在你們當時經歷的流程,以及這次你們可能預期的情況之間,有沒有什麼相似之處?
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
I appreciate the long-term memory, Craig.
Craig,我很感謝你這麼長期的記憶。
Yes. Certainly, we did think hard and long about that, as we thought about our forecast. It's why we haven't put much in the AI bucket 'cause, even if we sell or contract for a lot of (inaudible) -- business, we are worried that reviews may take a little while.
是的。當我們思考預測時,確實對此做了長時間、深入的思考。這也是為什麼我們在 AI 這個桶裡沒有放太多,因為即使我們賣出或簽下很多(聽不清)——的業務,我們仍擔心審查可能需要一些時間。
I'll say, as I look at this product, it's actually less new for our pharma clients than the vertical video was. It's hard to make vertical videos, especially three, four years ago, before we had a lot of AI tools to do it.
我會說,就我看這個產品而言,對我們的藥廠客戶來說,它其實比直式影片在當時更不算新。直式影片很難製作,尤其在三、四年前,在我們還沒有很多 AI 工具可用之前。
The reality is they just didn't have the content. You have to go literally hire an agency, make a video, do a video shoot, and clip it to together. That took a fair bit of time and review.
現實是他們就是沒有那些內容。你得真的去找一家代理商、製作影片、拍攝,然後把片段剪接在一起。那需要相當多的時間與審查。
I think, this time around, it's not about needing new assets, as they call it; new content. It's really just the reviews around the target keywords and the suppression words.
我認為這一次,重點不在於需要新的素材(他們稱之為 assets);新的內容。真正需要的是針對目標關鍵字與抑制詞(suppression words)的審查。
I think it will be faster this time. But we are taking a conservative approach.
我認為這次會更快。但我們採取保守的做法。
Craig Hettenbach - Analyst
Craig Hettenbach - Analyst
Understood. And then, just as my follow-up: You talked about putting the doctors first. You have PeerCheck and doing a lot of things to get this product situated.
了解。那接著追問:你談到把醫師放在第一位。你們有 PeerCheck,也做了很多事情來讓這個產品就位。
What else beyond that? Maybe it is that -- just relative to some of the other newer entrants in this space, like, what do you think is distinguishing Doximity the most today? What are you looking to build on to create some separation for new entrants?
除此之外還有什麼?也許是——相較於這個領域其他較新的進入者,你認為目前最能區分 Doximity 的是什麼?你們想在什麼方面持續打造,以便拉開與新進者的差距?
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Yeah. Thanks, Greg.
是的。謝謝你,Greg。
The number 1 thing I'll highlight is hospitals. At the end of the day, hospitals have a very difficult decision here. They do have some liability with the tools that their doctors use.
我想強調的第一件事是醫院。歸根結底,醫院在這裡面臨非常困難的決策。他們對醫師使用的工具確實承擔一定的責任風險。
What we have seen, from our data and usage, it's about half of all of the queries -- half of all the queries -- that doctors ask that have some amount of patient-protected information in it.
我們從數據與使用情況看到,大約有一半的查詢——醫師提出的所有查詢中有一半——包含某種程度的病患受保護資訊。
Of course, that is a huge concern for the security departments of these hospitals. We've seen a number of them start to lock down and block access to the wild west of AI that's out there.
當然,這對這些醫院的資安部門而言是巨大的疑慮。我們看到其中不少開始收緊管控,並封鎖外面那個 AI「蠻荒西部」的存取。
We're really proud that we've doubled our queries in a couple of months.
我們非常自豪在短短幾個月內把查詢量翻倍。
But I'd say I'm most proud -- it took us two full years with our telehealth product dialer. This was during COVID, when things were moving very fast. It took us two full years to get to 140 hospital enterprise clients. We've done that in two quarters with our AI product, which is pretty impressive.
但我會說我最自豪的是——我們的遠距醫療產品撥號器花了整整兩年。那是在 COVID 期間,事情進展非常快。我們花了整整兩年才達到 140 家醫院企業客戶。而我們的 AI 產品在兩個季度內就做到這件事,這相當令人印象深刻。
Now, we have over 250,000 doctors in the US -- a lot; more than anyone else -- who have the full HIPAA permission, HIPAA compliance, to put patient data in to our tools to help them provide better care, ask questions, get answers.
現在,我們在美國有超過 25 萬名醫師——很多;比任何人都多——具備完整的 HIPAA 授權與 HIPAA 合規,可以把病患資料輸入到我們的工具中,幫助他們提供更好的照護、提出問題並獲得答案。
I think that's a pretty sizable note.
我認為那是一筆相當可觀的票據。
Operator
Operator
Richard Close, Canaccord Genuity.
Richard Close,Canaccord Genuity。
Richard Close - Analyst
Richard Close - Analyst
Yes. Thanks for the questions.
是的。謝謝提問。
Maybe, Jeff, a follow-up on that 140 health systems, hospitals, that you just mentioned. Are these, generally speaking, upsells; they were existing Doximity clients?
或許,Jeff,針對你剛提到的那 140 家醫療體系、醫院再追問一下。一般來說,這些算是加購(upsell)嗎;他們原本就是 Doximity 的既有客戶嗎?
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Yeah. Richard, they mostly are folks who were existing clients. I think we've had a couple new clients, who were previously clients who came in.
對。Richard,他們多半是既有客戶。我想我們也有幾個新客戶,是以前曾經是客戶、後來又回來的。
But we have seven of the top 20 hospitals in the US. Again, we'll have more, next quarter, to talk about. They all have AI steering committees and reviews.
不過我們已經拿下美國前 20 大醫院中的 7 家。同樣地,下個季度我們會有更多可以分享。他們都有 AI 指導委員會與審查流程。
I will say that the process to get going here isn't just us adding a paragraph to a contract that already exists. It actually is a fairly exhaustive review process because, let's face it, people should be worried about their AI security and AI chaos, especially, again, when you're dealing with a lot of patient information.
我想說的是,啟動這件事的流程,不只是我們在既有合約上加一段文字而已。實際上這是一個相當全面的審查流程,因為說到底,大家確實應該擔心 AI 安全與 AI 失控,尤其是當你在處理大量病患資訊時。
Each of these has been a full process. But, again, we're at 140 now. We continue to grow.
每一個案子都是完整的一套流程。但如同我說的,我們現在已經到 140 家。我們還在持續成長。
We're proud, now, to also move beyond just working with the biggest health systems. But, Aledade, as we called out in our upfront script, they are the largest network of independent primary care practices in the country.
我們也很自豪,現在不只與最大的醫療體系合作。另外,Aledade——如同我們在開場稿中提到的——他們是全美最大的獨立基層醫療診所網路。
We're excited to work with Farzad and his team to make agentic AI for their teams using our Scribe and other tools.
我們很期待與 Farzad 及其團隊合作,運用我們的 Scribe 與其他工具,為他們的團隊打造代理式 AI(agentic AI)。
I think we've got a nice win here, where our AI is helping us win in the small practice, in addition to the big health systems.
我認為這是一個很好的勝利案例:我們的 AI 不僅幫助我們在大型醫療體系取勝,也能在小型診所端取勝。
Richard Close - Analyst
Richard Close - Analyst
Okay. That's helpful.
好的。這很有幫助。
And then, Perry, maybe on the shorter-duration comments, it seems that's a theme with some others that have reported. But what do you think has to happen or occur for pharma to move beyond the uncertainty? What are they waiting for to get more comfortable with either the pricing or policy environments?
接著,Perry,關於較短期間的評論,這似乎也是其他已公布業績者的共同主題。但你認為要發生什麼事,或具備什麼條件,製藥業才會走出不確定性?他們在等什麼,才會對定價或政策環境更有信心?
Perry Gold - Vice President - Investor Relations
Perry Gold - Vice President - Investor Relations
Richard, it's a great question.
Richard,這是個很好的問題。
I think the reality is it's coming from the C-suite down and the risk appetite is not terribly high, right now. I think, for better or worse, the policy and macro environment have to get a little bit better for there, maybe, to be a little more willingness to commit more money, upfront, for longer.
我認為現實是,這是由高層(C-suite)往下傳導的,而目前的風險承受度並不高。我想不管好壞,政策與總體環境需要稍微好轉一些,才可能讓大家更願意在前期投入更多資金、並做出更長期的承諾。
I think, eventually, some of these folks realize they're missing out on better economics by not doing that. I do think those are going to take a little time for macro and policy to get better.
我想最終有些人會意識到,不這麼做其實會錯失更好的經濟效益。但我確實認為,總體與政策環境改善還需要一些時間。
Hopefully, we'll some settlement to this war in Iran, at some point. I don't know if, after the midterm election, there's a little bit less noise around pharma policy. It's not our specialties calling these things. But I really think that's what has to happen.
希望伊朗這場戰爭在某個時點能有個和解。我不知道是否在期中選舉之後,圍繞製藥政策的雜音會少一些。這些並不是我們的專長去判斷。但我真的認為需要發生這些事情。
The other piece: Maybe it's showing -- getting people comfortable with our new product, AI Search. Eventually., the nice thing about what we have now in the early days -- and it's still very early -- there's a ton of competition we're seeing amongst brands and amongst sales reps, which is really nice to see.
另一個面向:也許是展示——讓大家對我們的新產品 AI Search 感到更安心。最終,現在早期階段的好處——而且仍然非常早——是我們看到品牌之間、以及業務代表之間有大量競爭,這點很樂見。
There is some level of selling these categories and competitive blunting. And so there are some brands that want to own a certain category. A lot of times, for the entire year, I think it's actually what they're going to want to go for.
某種程度上,這涉及到銷售這些品類與競爭鈍化(competitive blunting)。因此有些品牌想要主導某個特定品類。很多時候,我認為他們其實會想要爭取整年度的主導。
I think the ability to block out some competition, specifically through this product and selling to share a voice is one of those things that we think will get some folks to commit to longer than three-month contracts.
我認為,透過這個產品來阻擋部分競爭、並以「聲量份額」(share of voice)來銷售的能力,是我們認為能促使部分客戶承諾超過三個月合約的因素之一。
That may not happen until the next upfront cycle. But I do think there's a component of the competitive blunting that folks may want to leverage for longer-term contracts.
這可能要到下一次的 upfront 週期才會發生。但我確實認為,競爭鈍化這一塊,客戶可能會想用在更長期的合約上。
Operator
Operator
Ryan Halsted, RBC Capital Markets.
Ryan Halsted,RBC Capital Markets。
Ryan Halsted - Analyst
Ryan Halsted - Analyst
Good afternoon. Thanks for taking the question.
下午好。謝謝讓我提問。
Maybe just to dig into the bookings disclosures: Last quarter, you mentioned starting the year off at record bookings pace. Just curious to hear how that translated into billable revenue.
我想再深入一下訂單(bookings)揭露:上季你提到今年開局的訂單節奏創下紀錄。想請教這如何轉化為可開立帳單的營收(billable revenue)。
And then, obviously, you're guiding to a much slower pace of bookings growth. Just curious how all that has transpired?
另外,很明顯你們指引的是訂單成長速度會放慢很多。想了解這整體是如何演變的?
Perry Gold - Vice President - Investor Relations
Perry Gold - Vice President - Investor Relations
Hey, Ryan. Yes. It's a great question.
嗨,Ryan。是的。這是個很好的問題。
I think what I'll come back to is, January was record bookings growth for January. But January is, I think, the smallest month, bookings-wise, the entire year.
我想我會回到一點:一月是一月的訂單成長創下紀錄。但一月我認為是全年在訂單上最小的月份。
Some of that was simply delayed bookings -- things that should have signed by 12/31 that got pushed a little bit.
其中一部分只是延後簽約的訂單——原本應該在 12/31 前簽下的案子,被往後推了一點。
I think, as we went on to the future months, the market has remained soft. That's the reality.
我想隨著進入後續月份,市場仍然偏疲弱。這就是現實。
I think there's a lot of uncertainty; a lot of want for optionality. And so we haven't -- it's been, I think, a little bit incrementally worse than 90 days ago.
我認為不確定性很高;大家也很想保留彈性選擇。所以我們沒有——我覺得相較 90 天前又稍微更糟一些。
That's the reality. We didn't have a war in Iran 90 days ago.
這就是現實。90 天前我們還沒有伊朗戰爭。
I think that's maybe the disconnect between strength in January, which was, some of it was bookings from the prior year and not seeing that flow through, so far, this year.
我想這也許就是一月的強勁(其中一部分其實是前一年的訂單)與今年迄今尚未看到其轉化之間的落差。
That's the biggest factor.
這是最大的因素。
Ryan Halsted - Analyst
Ryan Halsted - Analyst
That's helpful. And then, my follow-up question, just on the upsell and the commentary around the shorter-term spend commitments; just looking for some clarification:
這很有幫助。接著我的追問,關於加購(upsell)以及你們對較短期支出承諾的評論;想請你們再釐清一下:
Typically, my understanding of the upsell period is you're talking about the reallocation of dollars over the remainder of the budget calendar year or fiscal year.
一般我對加購期間的理解是,你們談的是在剩餘的預算年度或會計年度內重新分配預算。
How should we think about that shorter-term spend commitment impacting that portion of those upsell dollars? Does that mean, like, some of that upsell dollars could be allocated beyond the budget year?
我們該如何看待較短期的支出承諾,對那部分加購金額的影響?這是否表示,有些加購金額可能會被配置到預算年度之外?
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Sure. This is Jeff. I'll take this.
當然。我是 Jeff。我來回答。
Listen, if we go back five years, I think most of what we sold were annual programs that they would layer on more to in the mid-year, right? That's how things work.
聽著,如果我們回到五年前,我想我們賣的大多是年度方案,而他們會在年中再往上加碼,對吧?事情就是這樣運作的。
We're in an environment, right now, where there's just a lot of change. The AI news cycle -- everything -- it's moving at a very rapid pace.
我們現在所處的環境是,變化非常多。AI 的新聞週期——所有事情——都在非常快速地推進。
The bad news is that that does hurt our visibility, when clients prefer to sign three- and six-month commitments.
壞消息是,當客戶偏好簽三個月或六個月的承諾時,這確實會影響我們的能見度。
The good news is, we do it at higher prices. Actually, we're quite explicit about that. The year-long contracts, they get decent discounts for those upfront commitments.
好消息是,我們會以更高的價格來做。其實我們在這點上講得很明確。一年期合約,因為他們願意提前做出承諾,所以會拿到不錯的折扣。
Clients understand that if they make shorter commitments, they pay higher prices. In the long run, it could work out to be better for us that we're getting better prices; again, still with a great ROI for our clients.
客戶明白,如果他們做出較短期的承諾,就必須支付更高的價格。從長期來看,對我們而言可能反而更好,因為我們能拿到更好的價格;同樣地,對我們的客戶而言仍然有很高的投資報酬率(ROI)。
They're making shorter commitments. But we're getting better pricing.
他們正在做出較短期的承諾。但我們拿到的定價更好。
I do think there is a larger shift here, as Perry has mentioned. Folks are just a little more tepid and the world is changing pretty quickly.
我確實認為這裡存在更大的轉變,正如 Perry 提到的。大家只是稍微更保守一些,而世界變化得相當快。
And so there is a few of the top 20 clients who have preferred to move away from the traditional annual commitments for their whole budget and for shorter commitments. But, again, in the long run, that can turn out to be good for us, from an overall revenue and profit perspective.
因此,前 20 大客戶中有幾家更傾向於不再採用傳統的全年承諾來涵蓋其整體預算,而改為較短期的承諾。但同樣地,從長期來看,從整體營收與獲利的角度,這可能對我們是好事。
It does mean, however, that we have less visibility. That comes out, obviously, in the guidance that we're providing.
不過,這確實意味著我們的可見度較低。這當然也反映在我們所提供的財測指引中。
Operator
Operator
Stephen Valiquette, Mizuho Securities.
Stephen Valiquette,瑞穗證券(Mizuho Securities)。
Steven Valiquette - Equity Analyst
Steven Valiquette - Equity Analyst
Yeah. Thanks. Yeah. Good afternoon. Thanks for taking the question.
是的。謝謝。是的。各位下午好。謝謝讓我提問。
Also, for us, continuing on this dialogue around the revenue outlook for digital marketing spend over the next year or so, just curious if you're able to maybe give a little more color as to whether or not certain therapeutic categories are worth calling out where you may see incremental or continued softness in marketing spend.
另外,延續我們對未來一年左右數位行銷支出營收展望的討論,我想請教你們是否能再多補充一些細節:是否有某些治療領域值得特別點名,可能會看到行銷支出出現增量的疲弱或持續走弱。
I ask because another public company talked about softness related to marketing spend in vaccines and also, like, GLP-1s, related to weight loss and/or in diabetes.
我之所以這樣問,是因為另一家上市公司提到,疫苗相關的行銷支出偏弱,另外像 GLP-1(與減重及/或糖尿病相關)也有類似情況。
I'm just curious if you're seeing those same trends or maybe it's just more broad-based to just get a little bit more color.
我想了解你們是否也看到相同趨勢,或是其實更偏向全面性(更廣泛)的現象,想請你們再多給一點顏色。
Thanks.
謝謝。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Sure. This is Jeff.
當然。我是 Jeff。
Yeah. We don't talk about individual clients. Yeah. I'll say this: Our GLP-1 business is growing very nicely, as you'd expect, right? That overall business is very competitive; certainly, a world where there's increased marketing spend. It's growing very nicely.
是的。我們不會談論個別客戶。是的。我可以這麼說:我們的 GLP-1 業務成長得非常好,這也符合你的預期,對吧?整體而言,那個市場競爭非常激烈;當然也是一個行銷支出增加的環境。它成長得非常好。
In terms of number of new FDA approvals and whatnot, it's a good year; not a great year but it's been a good year. We think it will continue to be a good year in other classes, as well.
就新的 FDA 核准數量等等來看,今年算是個不錯的一年;不是非常好,但確實是不錯的一年。我們認為在其他藥物類別方面,今年也會持續是不錯的一年。
Again, that's where we see a high percentage of the spend going towards healthcare professionals, as opposed to DTC. And so I think we'll continue to do well there.
再說一次,我們看到很高比例的支出是投向醫療專業人士(HCP),而不是直接面向消費者(DTC)。因此我認為我們在那裡會持續表現良好。
But, yeah, I will say there is clearly a few companies that are doing very well. We're doing very well with those companies.
不過,是的,我會說確實有幾家公司表現非常好。我們與那些公司合作也做得非常好。
It's funny, the overall [iShares Pharma ETF], it's basically flat, year to date, calendar year to date. But you are seeing, I think, more divergence, if you will, in which companies are doing well and which are not.
很有意思的是,整體的 [iShares Pharma ETF] 今年以來(年初至今)基本上持平。但我認為你確實看到更大的分化:哪些公司表現好、哪些公司表現不好。
That's always been the case. But I think a little more so now than, perhaps, it has been in a while.
這種情況一直都存在。但我覺得現在比起可能過去一段時間,分化更明顯一些。
But, again, on our book of business, we're seeing ourselves growing with the ones who are doing well and growing a little less with the ones who aren't.
不過,再回到我們的業務組合,我們看到自己在表現好的那些公司上成長得更快,而在表現不佳的公司上成長得稍微少一些。
I think you can just index us to the overall pharma growth.
我想你可以把我們視為與整體製藥產業成長大致同步。
Steven Valiquette - Equity Analyst
Steven Valiquette - Equity Analyst
That's helpful. Thank you.
這很有幫助。謝謝。
Operator
Operator
David Roman, Goldman Sachs.
David Roman,高盛(Goldman Sachs)。
David Roman - Analyst
David Roman - Analyst
Thank you. Good afternoon, everybody.
謝謝。各位下午好。
I wanted to start on just some of the market dynamics here. I think you've historically talked about the digital HCP pharma advertising market being in the $2.5 billion to $3 billion range. You've offered some perspective on the growth outlook here.
我想先從這裡的一些市場動態談起。我記得你們過去曾提到,數位 HCP 製藥廣告市場的規模大約在 25 億到 30 億美元之間。你們也提供過對這裡成長前景的一些看法。
But, on the paid AI Search side, appreciating it's a huge TAM you're going after, is there any frame of reference you can give us on size of that category today; what you think the serviceable addressable market is; and how much of the outlook is dependent on market creation versus shifting dollars over to this type of spend?
不過,在付費 AI 搜尋(paid AI Search)這一端,我理解你們瞄準的是一個非常大的 TAM(總可服務市場)。你們能否給我們一個參考框架:這個類別目前的規模大概是多少;你們認為可服務的可觸及市場(serviceable addressable market)有多大;以及你們的展望有多少是取決於市場創造(market creation),而不是把既有的預算轉移到這類支出上?
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Yeah. David, this is Jeff.
是的。David,我是 Jeff。
I got to be honest, this is a hard question to answer because this is genuinely a brand new market.
老實說,這個問題很難回答,因為這確實是一個全新的市場。
I'll highlight that with a stat. The average Google search is two-and-a-half words. Our average Doximity AI Search is 23 words. It's just a lot more context. It's really a very different approach.
我用一個數據來說明。Google 平均每次搜尋是 2.5 個字。我們 Doximity AI Search 的平均搜尋是 23 個字。它包含更多脈絡。這真的是非常不同的方法。
Even if you were able to identify who is an HCP on a paid-search site, which, frankly, you mostly can't, the amount of specificity around the question and the amount of insight really is at a whole new level.
即便你能在某個付費搜尋網站上辨識出誰是 HCP——坦白說,多數情況下你做不到——問題的具體程度以及所能得到的洞察,其實都提升到全新的層次。
It is a new TAM. I think it may end up being like what Google did to the Yellow Pages, right?
這是一個新的 TAM。我認為它最後可能會像 Google 對黃頁所做的事情一樣,對吧?
The Yellow Pages wasn't that big a business or, at least, it was a few billion. And then, very quickly, Google 10xed that business.
黃頁本來不是那麼大的生意——或者至少也就是幾十億美元規模。然後很快地,Google 把那個生意放大了 10 倍。
I think that, as we look at AI Search for medicine, we could end up creating a much bigger TAM than what currently exists in HCP paid search, even if we could clearly identify what percent is HCP paid search.
我認為,當我們看醫療領域的 AI 搜尋時,我們可能會創造出一個遠大於目前 HCP 付費搜尋所存在的 TAM;即便我們能清楚辨識出 HCP 付費搜尋占比到底是多少。
Hard question to answer. But I'll say this: The level of engagement from top pharmaceutical companies, off the charts.
這問題很難回答。但我可以說:來自頂尖製藥公司的參與度高得驚人。
The reality is this is something that's very exciting to see; and understand what are the real gaps and what are the real issues that frontline clinicians are encountering with my product.
事實上,看到這件事真的很令人振奮;並且能理解第一線臨床醫師在使用我的產品時,真正的缺口是什麼、真正的問題是什麼。
That, I think, will be good for healthcare, overall, 'cause I think we'll start to see better drug development and better education. We'll really start to, I think, get through all the layers to understand what the key issues and questions are.
我認為這對整體醫療保健會是好事,因為我覺得我們會開始看到更好的藥物研發與更好的教育。我想我們真的會開始穿透所有層次,去理解關鍵議題與關鍵問題到底是什麼。
Hard to put a number on that, right now.
目前很難為此給出一個數字。
David Roman - Analyst
David Roman - Analyst
Understood. Maybe just a follow-up; As you think about -- appreciating your comments on the macro environment; and some of the political and other uncertainty that have faced pharma companies --but coming out of Q1, most companies were raising their revenue outlets for the year. You're seeing your net revenue retention come down a little sequentially in quarter over quarter.
了解。也許再追問一下:在你們看待——我理解你們對總體環境的評論,以及製藥公司所面臨的一些政治與其他不確定性——但從第一季之後,多數公司都在上調今年的營收展望。你們看到你們的淨營收留存率(net revenue retention)在季對季上略有下降。
At what point do you ask yourselves -- or how do you reassure investors that pharma companies aren't figuring out how to do more with less; and the businesses are doing fine without deploying a lot of resources toward HCP advertising so this is going to be constrained for a longer period of time until they figure out the next area in which to invest?
你們在什麼時點會問自己——或者你們要如何讓投資人安心:製藥公司並不是在想辦法用更少資源做更多事;而且即使不投入大量資源在 HCP 廣告上,業務也運作得很好,因此這塊可能會在更長一段時間內受到限制,直到他們找到下一個要投資的領域?
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Thanks, David. This is Jeff. I'll take that.
謝謝,David。我是 Jeff。我來回答。
I think pharma companies will do more with less but we're the more. Today, they spend a lot on a lot of the mechanics, analytics, and data warehouses.
我認為製藥公司會用更少資源做更多事,但我們就是那個「更多」。今天,他們在許多機制、分析,以及資料倉儲上花了很多錢。
One KOL interview that one of the analysts did a couple of years ago asked what the fastest-growing area in digital HCP was. The answer was, spending on consulting firms, (inaudible)-- right, because of all of the consulting that needed to be done to measure the ROI of the programs.
幾年前,其中一位分析師做的一次 KOL 訪談問到,數位 HCP 領域成長最快的區塊是什麼。答案是:在顧問公司上的支出,(聽不清)——對,因為需要做大量顧問工作來衡量這些專案的 ROI。
And so this allows them to really put money where it works for them, which is where the ROI is.
因此,這讓他們能真正把錢花在對他們有效的地方,也就是 ROI 所在之處。
Again, I think we have always won on that front. We continue to grow there.
再說一次,我認為我們在這方面一直都贏。我們也持續在那裡成長。
I think there will be efficiency gains. That will accrue to us because, again, we're the ones who are delivering the ROI.
我認為會有效率提升。這些效益會歸於我們,因為再說一次,我們就是提供 ROI 的那一方。
Operator
Operator
Scott Schoenhaus, KeyBanc.
Scott Schoenhaus,KeyBanc。
Scott Schoenhaus - Equity Analyst
Scott Schoenhaus - Equity Analyst
Hey, team. Thanks for taking my question.
嗨,各位團隊。謝謝讓我提問。
Perry, this one's for you.
Perry,這題是問你的。
You cited market share growth at 5% or below and same expectations for your own growth. Maybe, what's the delta between your historic 2 times market share versus in-line market share? Is it more heavily weighted towards, maybe, a loss of market share on the AI side and a catch-up there or this downshift in temporary lower-cost spend from your clients?
你提到市占成長在 5% 或以下,且對你們自身成長的預期也相同。或許想問一下,你們過去「市占成長是市場的 2 倍」與現在「與市場同步」之間的差距(delta)是什麼?這是否更偏向於 AI 端市占流失、需要追趕,或是客戶暫時轉向較低成本投放所造成的下修?
Perry Gold - Vice President - Investor Relations
Perry Gold - Vice President - Investor Relations
Hey, Scott. It's a great question.
嗨,Scott。這是個很好的問題。
Yes. I think, historically, we've always outgrown the market some years more so than others. This year, if you look at our guide, we are looking like, at least at this point, we'll be more in line with the market; maybe slight outperformance.
是的。我認為從歷史上看,我們一直都比市場成長更快,只是有些年份超越得更多、有些年份較少。今年如果你看我們的指引,至少在目前這個時間點,我們看起來會更接近市場;也許會略微超越。
I think the reality is -- and you were talking about this earlier -- there isn't a lot of incremental budget. We saw this three years ago.
我認為現實情況是——你剛才也提到——並沒有太多新增預算。三年前我們也看過這種情況。
We didn't have, really, something very innovative in the AI Search commercial department to offer folks until two weeks ago. We weren't there in the upfront cycle to provide this.
在兩週前之前,我們在 AI Search 的商業部門其實沒有什麼非常創新的東西可以提供給大家。我們也沒有在前期(upfront)週期中就到位來提供這個。
But, now, we have something. We're playing a little bit of catch-up on the commercial front. We're really excited about what we have to offer. That, I think will help us.
但現在,我們有了。在商業面我們正在稍微追趕一下。我們對我們能提供的內容感到非常興奮。我認為這會幫助我們。
The reality is -- and to Jeff's point earlier -- because of the med-legal review timeline, right, you lose the summer for most of these programs going live. And so you have real revenue coming from them in the third quarter -- the fiscal third quarter -- so October through December; maybe a little bit before.
現實是——也呼應 Jeff 先前的觀點——由於醫療-法務審查的時程,對吧,你會錯過夏季,因為多數專案要到那之後才會上線。因此,你會在第三季——會計年度第三季——也就是 10 月到 12 月,開始看到它們帶來實質營收;也可能稍早一點。
But you're losing out on most of the calendar year having this innovative product in market, when you're recognizing revenue, right? That's part of why it's a little harder to outgrow this year.
但你等於在整個曆年大部分時間裡都少了這個創新產品在市場上、也就少了你能認列營收的時間,對吧?這也是為什麼今年要超越市場成長會比較困難的一部分原因。
The other piece, to your point, on the the want for maybe some discounts, some lower-cost engagements or impressions, that's just not where we play.
另外一點,回到你提到的,客戶可能想要一些折扣、一些更低成本的合作或曝光量,那就不是我們的戰場。
I think, three years ago, we went through something similar. I think there were some legacy publishers also offering discounts, at that time. Maybe we lost a little bit of share of the margin.
我認為三年前我們也經歷過類似情況。我記得當時也有一些傳統出版商提供折扣。也許我們在利潤率上稍微讓出了一點市占。
But, longer term, we're in a way better position by sticking to what we do best: a premium physician-first offering. That's the strategy that has paid off over the long term.
但從長期來看,堅持我們最擅長的事情:以醫師為先的高端產品,我們的處境會好得多。這就是長期以來奏效的策略。
We've been around for 16 years. We've been through multiple technology cycles. We might be a little late initially on the commercial front but, in the long run, we have the much better product; the much better physician uptake; the premium offering. We eventually have the better share gains.
我們已經成立 16 年了。我們經歷過多個技術週期。在商業面一開始我們可能會稍微晚一點,但長期來看,我們有更好的產品;更高的醫師採用度;更高端的產品。最終我們會取得更好的市占提升。
I think, longer term, we are very well positioned to continue to outgrow the market.
我認為從長期來看,我們非常有利於持續跑贏市場成長。
Our engagement's never grown faster. I think, over time, the revenue eventually follows that engagement growth; that engagement trajectory. I think, when folks are ready to come back to the premium-high ROI channels, we will be there in force.
我們的互動(engagement)從未成長得這麼快。我認為隨著時間推進,營收最終會跟上互動成長;跟上這條互動軌跡。我認為當大家準備回到高端、高 ROI 的渠道時,我們會強勢在場。
I'll also just add -- I think it was -- [Allen] put out a survey he's been doing for a few years. When folks were asked; pharma brands were asked, who's the platform where you're going to give your money, if and when you have incremental budget, we were, by far, the leader there.
我再補充一點——我想是——[Allen] 發布了一份他做了幾年的調查。當大家被問到;藥廠品牌被問到,如果、以及當你有新增預算時,你會把錢投到哪個平台,我們在那裡遙遙領先。
We had the biggest jump, I think, we've ever had. Clearly, when people get money, they want to spend with us.
我認為那是我們有史以來最大的一次躍升。很明顯,當人們有錢時,他們想把預算花在我們這裡。
I think we're well positioned, if and when some budget unlocks, hopefully, a little bit more this year.
我認為如果、以及當一些預算解鎖時,我們已經準備好了——希望今年能多一些。
Matt Sonefeldt - Chief Financial Officer
Matt Sonefeldt - Chief Financial Officer
Scott, I'll just jump in really quickly, too. This is from a total newcomer's perspective. I'm not here full-time quite yet.
Scott,我也很快插一句。這是從一個完全新加入者的角度來看。我還沒有正式全職加入。
I think by being an operator in platform companies; by having invested in platform companies, like, I've been really impressed with how the team's been super disciplined on focusing on the physician-first engagement side of the market and creating that.
我認為,作為平台公司的經營者;也投資過平台公司,我對團隊在聚焦「以醫師為先」的市場互動面向、並打造它這件事上所展現的高度紀律性印象非常深刻。
Because that, ultimately, is what will create the longer-term growth opportunity.
因為最終,這才會創造長期的成長機會。
I think, now, it's time to invest, as well in the pharma-client experience around that much stronger engagement.
我認為現在也到了該投資的時候——也就是在這個更強互動之上,去投資藥廠客戶的使用體驗。
But you don't really see your base of users all that often go through dramatic acceleration points. Doximity's seeing that, right now; really driven by the AI engagement.
但你不太常看到你的使用者基礎出現如此劇烈的加速拐點。Doximity 現在正看到這種情況;主要是由 AI 互動所驅動。
I think that's just a really exciting longer-term framing opportunity to think about how AI monetization really starts to play into the model.
我認為這是一個非常令人興奮的長期框架機會,去思考 AI 變現如何真正開始融入這個模型。
Operator
Operator
Ladies and gentlemen, that concludes our question-and-answer session.
各位女士、先生,我們的問答環節到此結束。
I will now turn the conference back over to Mr. Jeff Tangney for closing remarks.
接下來我將把會議交回給 Jeff Tangney 先生作結語。
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
Jeffrey Tangney - Chief Executive Officer, Co-Founder, Director
I'd like to just thank the entire Doximity team for their hard work in serving more doctors every day than ever before.
我想感謝整個 Doximity 團隊的辛勤付出,讓我們每天服務的醫師人數都比以往任何時候更多。
Thank you, everyone, for joining.
謝謝各位的參與。
Operator
Operator
Ladies and gentlemen, this concludes today's call.
各位女士、先生,今天的電話會議到此結束。
We thank you for your participation.
感謝各位的參與。
You may now disconnect.
您現在可以掛線。